[AML-XH-99-M3方案治疗儿童急性早幼粒细胞白血病的疗效]

[Effectiveness of the AML-XH-99-M3 protocol for treatment of acute promyelocytic leukemia in children].

作者信息

Chen Jing, Gu Long-Jun, Tang Jing-Yan, Xue Hui-Liang, Pan Ci, Ye Qi-Dong, Jiang Hua, Dong Lu, Zhou Min, Wang Yao-Ping

机构信息

Department of Hematology/Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medcine, Shanghai 200127, China.

出版信息

Zhongguo Dang Dai Er Ke Za Zhi. 2008 Jun;10(3):329-32.

PMID:18554461

Abstract

OBJECTIVE

To evaluate the effectiveness of AML-XH-99-M3 protocol for treatment of acute promyelocytic leukemia (APL) in children.

METHODS

Thirty-three children with APL received AML-XH-99-M3 protocol treatment. The event-free survival (EFS), disease-free survival (DFS), and overall survival (OS) were evaluated by the Kaplan-Meier medthod with SPSS13.0 software.

RESULTS

Thirty patients (90.9%) achieved a complete remission (CR) after one course of treatment. The total CR rate was 100%. Six patients (18.2%) relapsed in an average of 29.17 months (16-38 months). Two patients (6.1%) died. The 7-year EFS and DFS in the 30 patients were 73.4+/-9.4%. The overall survival rate was 91.2+/-6.0%. The difference of EFS was observed in patients receiving intermittent all-trans-retinoic acid (ATRA) administration or not in the maintenance therapy (88.9+/-10.5% vs 62.5+/-13.6%) (P<0.05).

CONCLUSIONS

The AML-XH-99-M3 protocol for the treatment of APL produced a higher CR rate and higher EFS, DFS and OS rates in children. Intermittent administration of ATRA in the maintenance therapy can improve EFS rate.

摘要

目的

评估AML-XH-99-M3方案治疗儿童急性早幼粒细胞白血病（APL）的疗效。

方法

33例APL患儿接受AML-XH-99-M3方案治疗。采用Kaplan-Meier法，利用SPSS13.0软件评估无事件生存（EFS）、无病生存（DFS）和总生存（OS）情况。

结果

30例（90.9%）患儿经过1个疗程治疗后达到完全缓解（CR），总CR率为100%。6例（18.2%）患儿复发，平均复发时间为29.17个月（16 - 38个月）。2例（6.1%）患儿死亡。30例患儿的7年EFS和DFS为73.4±9.4%。总生存率为91.2±6.0%。维持治疗中接受或未接受间歇性全反式维甲酸（ATRA）治疗的患儿EFS存在差异（88.9±10.5%对62.5±13.6%）（P<0.05）。